[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Salzburger Landeskliniken\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":167},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,82,116,141],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100644641","t6a-biomarker-for-detection-of-bacterial-infection-in-newborn-infants-100644641",false,"NCT07670624","T6A Biomarker for Detection of Bacterial Infection in Newborn Infants","T6ASepsis","Inclusion Criteria:\n\n* Newborn infants who require blood testing for screening for bacterial infection OR treating physician suspects bacterial infection in newborn infant\n* Signed informed consent form\n\nExclusion Criteria:\n\n1. Refusal to participate in study or not providing written informed consent by caregivers\u002Fparents\n2. Antibiotic treatment of any kind.","ALL",{"count":18,"type":19},210,"ESTIMATED","1 Week","OBSERVATIONAL","This study aims to assess the efficacy of a new biomarker, N6-threonylcarbamoyladenosine (t6A), for the early diagnosis of Early-Onset Sepsis (EOS) in newborns.",[24,25,26],"Sepsis","Newborn Sepsis","Biomarker Discovery",[28,29,30,31],"t6a","newborn sepsis","infectious disease biomarker","biomarker","NOT_YET_RECRUITING","2026-06-25",{"date":35,"type":36},"2026-06-26","ACTUAL",{"date":38,"type":19},"2026-07-01",{"date":40,"type":19},"2029-01-31",{"name":42,"class":43},"Salzburger Landeskliniken","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100560650","combining-high-frequency-micro-ultrasound-and-multiparametric-mri-target-biopsy-for-detecting-prostate-cancer-100560650","NCT06579911","Combining High-frequency Micro-ultrasound and Multiparametric MRI Target Biopsy for Detecting Prostate Cancer","Combining High-frequency Micro-ultrasound Target Biopsy and Multiparametric MRI Target Biopsy - Does it Increase the Detection Rate of Clinically Significant Prostate Cancer? A Prospective, Interventional, Single Centre, Randomized Controlled Trial","Biopsy29","Inclusion Criteria:\n\n\\- Men with suspected clinically significant prostate cancer, identified by the rise in PSA level, suspicious digital rectal examination or both and pathologic multiparametric MRI of the prostate (\\>= PI-RADS III)\n\nExclusion Criteria:\n\n* Patients with histopathologic proven prostate cancer\n* PSA \\> 20 ng\u002Fml\n* Finding in digital rectal examination \\>= cT2c\n* Untreated bacterial infection of the prostate\n* Untreated coagulopathy",true,"MALE","18 Years","99 Years",{"count":57,"type":19},400,"INTERVENTIONAL",[60],"NA","\\*\\*Study Goal:\\*\\* The purpose of this clinical trial is to determine if combining high-frequency micro-ultrasound with multiparametric MRI biopsy and a systematic biopsy can better detect clinically significant prostate cancer compared to current standard methods. This study is aimed at men who may have prostate cancer.\n\n\\*\\*Main Questions the Study Aims to Answer:\\*\\*\n\n1. Does the combination of new biopsy methods detect more clinically significant prostate cancers than the current standard method?\n2. Does the new method not increase the detection of less serious forms of cancer beyond what the standard method detects?\n\n\\*\\*Participation in the Study:\\*\\*\n\nParticipants in this study will undergo the following procedures:\n\n* A high-frequency micro-ultrasound examination of the prostate.\n* A multiparametric MRI-targeted biopsy of the prostate.\n* A systematic biopsy of the prostate.\n\n\\*\\*Comparison Group:\\*\\* Researchers will compare the new combination method with the current standard method to see if the new approach is more effective.\n\n\\*\\*Participants will:\\*\\*\n\n* Undergo several exams and biopsies depending on the results of previous tests.\n* Attend regular follow-up appointments to monitor potential side effects and evaluate prostate health.\n* Record their experiences and any symptoms in a diary.",[63],"Prostatic Neoplasm of Uncertain Behavior",[65,66,67,68,69,70,71],"Prostate cancer","prostate biopsy","high frequency ultrasound","fusion biopsy","multiparametric mri of prostate","pirads","primus","RECRUITING","2026-06-05",{"date":75,"type":36},"2026-06-09",{"date":77,"type":36},"2023-11-01",{"date":79,"type":19},"2028-01-01",{"name":42,"class":43},1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":58,"phases":91,"briefSummary":92,"conditions":93,"keywords":98,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},"100574042","assessing-ai-supported-fracture-detection-in-emergency-care-units-100574042","NCT06754137","Assessing AI-Supported Fracture Detection in Emergency Care Units","Evaluating the Cost-Efficiency and Workflow Impact of AI-Supported Fracture Detection in an Orthopedic Emergency Care Unit","Inclusion Criteria:\n\n* Presenting to the emergency department with an isolated injury or joint complaint\n* Patients able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Patients with injuries or complaints involving multiple body regions\n* Patients with prior imaging of the affected extremity or region within the past 6 months\n* Contraindications to X-ray imaging (e.g., pregnancy or severe instability)\n* Patients with other ongoing studies that may interfere with this study\n* Patients unable to provide consent due to cognitive impairment or language barriers without an available representative.",{"count":90,"type":19},4800,[60],"Brief Summary The purpose of this study is to determine if artificial intelligence (AI) can assist doctors in detecting broken bones, effusions, dislocations and bone lesions more quickly and accurately in an emergency room setting. The study will also evaluate whether AI can save time and reduce costs in healthcare.\n\nThe main questions to be addressed are:\n\n* Does AI improve the accuracy of detecting broken bones\u002Fdislocations\u002Feffusions\u002Fbone lesions?\n* Can AI expedite the process of diagnosing broken bones\u002Fdislocations\u002Feffusions\u002Fbone lesions?\n* Does AI reduce healthcare costs by enhancing efficiency?\n\nTo investigate these questions, two groups of patients will be compared. One group will follow the traditional diagnostic approach, while the other group will utilize AI to assist in diagnosing X-rays.\n\nParticipants in the study will:\n\nUndergo standard X-ray imaging of injured arms or legs, as part of routine care.\n\nHave X-rays reviewed by doctors with or without AI support, depending on the assigned group.\n\nThe study will include patients of all ages presenting to the emergency room with an isolated injury or joint complaints. No additional tests or treatments beyond standard care will be involved.",[94,95,96,97],"Fractures, Bone","Effusion Joint","Bone Lesion","Dislocation",[99,100,101,102,103,104,105,106,97,96],"Artificial Intelligence","Fracture Detection","Emergency Care","Cost-Efficiency","AI-Assisted Diagnosis","Diagnostic Accuracy","Orthopedic Diagnostics","Effusion","2026-01-20",{"date":109,"type":36},"2026-01-22",{"date":111,"type":36},"2025-03-31",{"date":113,"type":19},"2026-04-30",{"name":42,"class":43},3,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":52,"sex":16,"minAge":54,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":81},"100617005","analysis-of-nfl-and-gfap-in-different-dietary-patterns-100617005","NCT07312994","Analysis of NfL and GFAP in Different Dietary Patterns","Vegan, Vegeratian, or Omnivore: Dietary Effects on the Brain Tissue Biomarkers","Inclusion Criteria:\n\n* Healthy individuals who have followed a vegan, vegetarian, or omnivorous diet for at least one consecutive year\n* Aged between 18 and 40 years\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Diagnose neurological disorders (e.g. neurodegenerative, inflammatory, autoimmune, infectious, vascular)\n* Eating disorders\n* Excessive alcohol consumption\n* Pregnancy\n* Recent moderate to severe infection (within the past 12 weeks) , including SARS-CoV-2\n* Recent trauma, injury, or surgery (within the past 12 weeks)\n* Significant BMI fluctuations (\\>5 points) within the last year\n* Patients who have been using Proton pump inhibitors (PPIs) for an extended period (e.g., 1 month).","40 Years",{"count":125,"type":19},300,"This observational study aims to investigate the impact of different dietary patterns on brain tissue biomarkers in healthy young adults by measuring blood levels of NfL and GFAP.\n\nThe primary research question is: Do vegan, vegetarian, or omnivorous diets influence NfL and GFAP levels?",[128,129,130,131,132],"Neurofilament Light Chain","Glial Fibrillary Acidic Protein","GFAP","Vegan Diet","Vegetarian Diet","2025-12-17",{"date":135,"type":36},"2025-12-31",{"date":137,"type":36},"2025-12-18",{"date":139,"type":19},"2026-09",{"name":42,"class":43},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":58,"phases":150,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":166},"100378229","phase-2-nivolumab-for-treatment-of-squamous-cell-carcinoma-of-the-skin-100378229","NCT04204837","Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin","Phase II Study of Nivolumab (Group 1) and Nivolumab Plus Relatlimab (Group 2) in Patients With Locally Advanced\u002F Metastatic Squamous Cell Carcinoma of the Skin","Inclusion Criteria:\n\n1. Men and women, 18 years of age and older on day of signing written informed consent\n2. Histologically or cytologically documented locally-advanced and\u002For metastatic squamous cell carcinoma of the skin (stage III\u002FIV AJCC 2010) that is incurable\n3. Archival tumor tissue available for evaluation of PD-L1 and LAG-3 expression\n4. Measurable disease based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\n5. Life expectancy of at least 12 weeks\n6. Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2\n7. Screening laboratory values must meet the following criteria and should be obtained within 14 days prior to registration:\n\n   * WBC ≥ 2000\u002Fμl\n   * Neutrophils ≥ 1500\u002FμL\n   * Platelets ≥ 100 x103\u002FμL\n   * Hemoglobin \\> 9.0 g\u002FdL\n   * Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL\u002Fmin (if using the Cockcroft-Gault formula below):\n\n   Female CrCl = (140 - age in years) x weight in kg x 0.85\u002F72 x serum creatinine in mg\u002FdL Male CrCl = (140- age in years) x weight in kg x 1.00\u002F72 x serum creatinine in mg\u002FdL\n   * AST\u002FALT ≤ 3 x ULN\n   * Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin \\\u003C 3.0 mg\u002FdL)\n   * Negative pregnancy test and effective contraception (Pearl-Index \\\u003C1) for for women of childbearing potential (WOCBP) if the risk of conception exists\n8. Prior radiotherapy must have been completed at least 2 weeks prior to study drug administration\n9. Prior systemic antibiotic treatment must have been completed at least 30 days prior to stool sample collection\n\nExclusion Criteria:\n\n1. Patient is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment\n2. Prior therapy with CTLA-4, PD-1 or LAG-3 antibodies\n3. History of myocarditis, regardless of etiology\n4. Troponin T (TnT) or I (TnI) \\> 2× institutional upper limit of normal (ULN). Participants with TnT or TnI levels between \\> 1× to 2× ULN will be permitted if repeat levels within 24 hours are ≤ 1× ULN. If TnT or TnI levels are between \\> 1× to 2× ULN within 24 hours, the participant may undergo a cardiac evaluation and be considered for treatment, based on a favorable benefit\u002Frisk assessment by the Investigator. When repeat levels within 24 hours are not available, a repeat test should be conducted as soon as possible. If TnT or TnI repeat levels beyond 24 hours are \\\u003C 2× ULN, the participant may undergo a cardiac evaluation and be considered for treatment, based on a favorable benefit\u002Frisk assessment by the Investigator\n5. A condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses \\> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease\n6. Known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n7. Known additional malignancy that is progressing or requires active treatment. Patients with chronic lymphocytic leukemia that is stable under active therapy are eligible for inclusion.\n8. An active, known or suspected autoimmune disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger\n9. Patients with serious intercurrent illness, requiring hospitalization\n10. Other serious illnesses, e.g. serious infections requiring antibiotics\n11. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n12. Pregnancy (absence to be confirmed by ß-HCG urinary test, minimum sensitivity 25 IU\u002FL or equivalent units of HCG)) or lactation period\n13. Women of childbearing potential (WOCBP): Refusal or inability to use effective means of contraception (Pearl-Index \\\u003C1)\n14. History of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)\n15. Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection\n16. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator\n17. Known hypersensitivity reaction to any of the components of study treatment",{"count":149,"type":19},61,[151],"PHASE2","To determine the Objective Response Rate (ORR) of immunotherapy with Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in patients with locally advanced\u002Fmetastatic squamous cell carcinoma of the skin using Response Criteria in Solid Tumors Version 1.1 (RECIST1.1) per site assessment (Time Frame Group 2: From first dose up to 5 years)",[154],"Squamous Cell Carcinoma of the Skin",[156,157],"Nivolumab","Relatlimab","2024-04-17",{"date":160,"type":36},"2024-04-18",{"date":162,"type":36},"2017-03-06",{"date":164,"type":19},"2027-12",{"name":42,"class":43},7,""]